Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Ponatinib Plus Reduced-intensity Chemo Could Be New SOC in Newly Diagnosed Ph+ ALL

June 9th 2023

Treatment with ponatinib plus reduced-intensity chemotherapy led to an improvement in minimal residual disease-negative complete remission rate compared with imatinib plus reduced-intensity chemotherapy in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Dr Gill on the Evaluation of Oral Arsenic Trioxide Plus ATRA/Ascorbic Acid in APL

June 9th 2023

Harry Gill, MD, FRCP, FRCPath, discusses the investigation of an all-oral combination of arsenic trioxide, all trans retinoic acid, and ascorbic acid in patients with newly diagnosed acute promyelocytic leukemia.

Dr Jabbour on the Efficacy of Ponatinib in Newly Diagnosed Ph+ ALL

June 9th 2023

Elias Jabbour, MD, discusses efficacy data from the phase 3 PhALLCON trial of ponatinib plus reduced-intensity chemotherapy vs imatinib plus reduced-intensity chemotherapy in newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma

June 7th 2023

Treatment with the combination of epcoritamab, rituximab, and lenalidomide led to responses and durable remissions in patients with relapsed/refractory follicular lymphoma.

Gaining Ground in Gynecologic and Hematologic Cancers at ASCO 2023: Drs Herrera, Westin, and Jabbour

June 5th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Nivolumab With AVD Confers PFS Benefit Vs Brentuximab Vedotin Plus AVD in Advanced-stage Hodgkin Lymphoma

June 4th 2023

Nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (AVD) resulted in prolonged progression-free survival (PFS) compared with brentuximab vedotin plus AVD in patients with advanced-stage classical Hodgkin lymphoma.

Dr Roddie on Obe-cel in R/R B-ALL

June 3rd 2023

Claire Roddie, MD, discusses the patient population and topline efficacy findings from the phase 1/2 FELIX trial, which is investigating the CD19-directed CAR T-cell therapy obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.

Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL

June 2nd 2023

Brexucabtagene autoleucel elicited high rates of complete remission with minimal residual disease negativity in real-world patients with relapsed or refractory B-cell acute lymphoblastic leukemia who received the CAR T-cell product as post-approval, standard-of-care treatment, according to data from a retrospective study.

Dr Garcia-Manero on Luspatercept in Lower-Risk MDS

June 2nd 2023

Guillermo Garcia-Manero, MD, discusses key efficacy and safety findings from the phase 3 COMMANDS trial (NCT03682536) of luspatercept-aamt (Reblozyl) vs epoetin alfa in patients with lower-risk myelodysplastic syndrome.

Dr Zeidan on Imetelstat in Lower-Risk MDS

June 2nd 2023

Amer Zeidan, MBBS, discusses topline efficacy findings from the IMerge trial of imetelstat in patients with transfusion-dependent lower-risk myelodysplastic syndrome.

Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL

June 2nd 2023

Obecabtagene autoleucel was associated with a 76% complete response (CR)/CR with incomplete count recovery rate in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS

June 2nd 2023

Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial.

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

May 29th 2023

Dr Andreeff discusses the evaluation of uproleselan for the treatment of patients with acute myeloid leukemia, the rationale for targeting E-selectin in patients with this disease, how uproleselan could amplify the effects of chemotherapy in the treatment of these patients.

Quizartinib Garners Approval in Japan for Newly Diagnosed FLT3-ITD+ AML

May 26th 2023

Japan’s Ministry of Health, Labour, and Welfare has approved quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation and as maintenance monotherapy in patients with newly diagnosed acute myeloid leukemia whose tumors harbor FLT3-ITD mutations.

Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study

May 25th 2023

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Voruciclib With or Without Venetoclax Shows Safety, Activity in R/R AML, B-cell Malignancies

May 24th 2023

Voruciclib monotherapy and in combination with venetoclax demonstrated clinical activity and was well tolerated with no significant myelosuppression in heavily pretreated patients with relapsed/refractory acute myeloid leukemia or B-cell malignancies, according to initial data from a phase 1 trial.

OncLive Honors 12 Cancer Care Pioneers

May 22nd 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Dr Phillips on the FDA Approval of Epcoritamab in R/R DLBCL

May 19th 2023

Tycel Phillips, MD, discusses the significance of the FDA approval of the bispecific antibody epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Omidubicel Approval Represents Key Advance for Patients With Blood Cancers Requiring Transplant

May 19th 2023

Mitchell E. Horwitz, MD, expands on key efficacy and safety data supporting the FDA approval of omidubicel, the significance of this decision for the blood cancer treatment paradigm, and the need for continued investigation of the agent in non-malignant disease and other patient subgroups.